Praxis Precision Medicines (PRAX) Corporate presentation summary

Strategic vision and mission

• Focused on delivering transformative treatments for CNS disorders with urgent patient needs.

• Aims to repeatedly bring life-altering therapies to market faster and more effectively.

Portfolio and commercial potential

• Late-stage portfolio includes ulixacaltamide, relutrigine, vormatrigine, and elsunersen, targeting essential tremor, epilepsy, and rare CNS disorders.

• Combined commercial potential exceeds $20 billion in peak revenue.

• Multiple assets have received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations.

Clinical pipeline and innovation platforms

• Two innovation platforms: Cerebrum™ (small molecules) and Solidus™ (ASO therapies) enable repeatable CNS drug development.

• Pipeline spans preclinical to NDA stage, with precision therapies for both common and rare CNS indications.